{"groups":[{"description":"All subjects received bortezomib 1.3mg/m\\^2 on Days 1, 4, 15, and 18 every 28 days and dexamethasone 20mg daily on Days 1, 2, 4, 5, 15, 16, 18, and 19 every 28 days. Following US FDA approval of doxorubicin HCl liposome injection in combination with bortezomib in May 2007, the study was amended to allow combination treatment with both bortezomib and doxorubicin HCl liposome injection 30 mg/m\\^2 on Day 4 every 28 days with dexamethasone. The target goal was 8 cycles of treatment.","id":"FG000","title":"Treatment Group"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"32"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"32"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Informed consent was obtained from all subjects. All subjects underwent screening procedures to verify eligibility.","recruitmentDetails":"15 community oncology research sites across the US within the ACORN network participated in this study. Enrollment started in July 2006 but was stopped in December 2008 at the point when it became clear that enrollment was too slow to complete the planned enrollment target of 45 patients within the time frame allowed."}